Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. by Barbara H Stokes, Euna Yoo, James M Murithi, Madeline R Luth, Pavel Afanasyev, Paula C A da Fonseca, Elizabeth A Winzeler, Caroline L Ng, Matthew Bogyo, David A Fidock

Get full text

The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957 by Celia Miguel-Blanco, James M. Murithi, Ernest Diez Benavente, Fiona Angrisano, Katarzyna A. Sala, Donelly A. van Schalkwyk, Manu Vanaerschot, Frank Schwach, Matthew J. Fuchter, Oliver Billker, Colin J. Sutherland, Susana G. Campino, Taane G. Clark, Andrew M. Blagborough, David A. Fidock, Esperanza Herreros, Francisco Javier Gamo, Jake Baum, Michael J. Delves

Get full text

A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin by Deyun Qiu, Jinxin V. Pei, James E. O. Rosling, Vandana Thathy, Dongdi Li, Yi Xue, John D. Tanner, Jocelyn Sietsma Penington, Yi Tong Vincent Aw, Jessica Yi Han Aw, Guoyue Xu, Abhai K. Tripathi, Nina F. Gnadig, Tomas Yeo, Kate J. Fairhurst, Barbara H. Stokes, James M. Murithi, Krittikorn Kümpornsin, Heath Hasemer, Adelaide S. M. Dennis, Melanie C. Ridgway, Esther K. Schmitt, Judith Straimer, Anthony T. Papenfuss, Marcus C. S. Lee, Ben Corry, Photini Sinnis, David A. Fidock, Giel G. van Dooren, Kiaran Kirk, Adele M. Lehane

Get full text